Armas Federica, Camperio Cristina, Marianelli Cinzia
Department of Food Safety and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy.
Department of Sciences, Roma Tre University, Rome, Italy.
PLoS One. 2017 Jan 9;12(1):e0169543. doi: 10.1371/journal.pone.0169543. eCollection 2017.
Mastitis in dairy ruminants is considered to be the most expensive disease to farmers worldwide. Recently, the intramammary infusion of lactic acid bacteria has emerged as a potential new alternative to antibiotics for preventing and treating bovine mastitis. In this study we have investigated in vitro the probiotic potential of Lactococcus lactis LMG 7930, a food-grade and nisin-producing strain, against mastitis-causing pathogens. We have characterized its carbohydrate fermentation and antibiotic susceptibility profiles, cell surface properties and antimicrobial activity, as well as its capabilities to adhere to and inhibit the invasion of pathogens into the bovine mammary epithelial cell line BME-UV1d. We found that L. lactis LMG 7930 was sensitive to tested drugs, according to the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), and showed an improved carbohydrate fermentation capacity compared to starter strains. Moreover, the strain exhibited antagonistic properties towards many of the pathogens tested. It presented medium surface hydrophobicity, a low basic property and no electron acceptor capability. It showed low auto-aggregation and no co-aggregation abilities towards any of the tested pathogens. The strain was one of the most adhesive to bovine mammary epithelial cells among tested bacteria, but its internalisation was low. The strain did not affect significantly pathogen invasion; however, a trend to decrease internalization of some pathogens tested was observed. In conclusion, our results suggest that this strain might be a promising candidate for the development of new strategies of mastitis control in ruminants. Future investigations are needed to evaluate its safety and efficacy under field conditions.
奶牛乳腺炎被认为是全球奶农面临的最昂贵疾病。最近,向乳房内注入乳酸菌已成为预防和治疗奶牛乳腺炎的一种潜在新抗生素替代品。在本研究中,我们在体外研究了食品级且产乳链菌肽的乳酸乳球菌LMG 7930对引起乳腺炎的病原体的益生菌潜力。我们对其碳水化合物发酵和抗生素敏感性谱、细胞表面特性和抗菌活性,以及其黏附于和抑制病原体侵入牛乳腺上皮细胞系BME-UV1d的能力进行了表征。我们发现,根据欧洲食品安全局动物饲料添加剂和产品或物质专家委员会(FEEDAP)的标准,乳酸乳球菌LMG 7930对测试药物敏感,并且与发酵剂菌株相比,其碳水化合物发酵能力有所提高。此外,该菌株对许多测试病原体表现出拮抗特性。它具有中等表面疏水性、低碱性且无电子受体能力。它显示出低自聚集性,并且对任何测试病原体均无共聚集能力。该菌株是测试细菌中对牛乳腺上皮细胞黏附性最强的菌株之一,但其内化作用较低。该菌株对病原体侵入没有显著影响;然而,观察到一些测试病原体的内化作用有降低趋势。总之,我们的结果表明,该菌株可能是开发反刍动物乳腺炎控制新策略的有前途的候选菌株。需要进一步的研究来评估其在田间条件下的安全性和有效性。